Last Updated: May 10, 2026

List of Excipients in Branded Drug ASSURED IBUPROFEN


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for ASSURED IBUPROFEN

Last updated: March 1, 2026

What is the current excipient profile for ASSURED IBUPROFEN?

The formulation of ASSURED IBUPROFEN typically includes the active pharmaceutical ingredient (API) ibuprofen at 200 mg per tablet. Common excipients in OTC formulations include microcrystalline cellulose (filler and binder), croscarmellose sodium (disintegrant), magnesium stearate (lubricant), and colloidal silica (glidant). In modified-release versions, these may be supplemented with controlled-release polymers such as hydroxypropyl methylcellulose (HPMC).

How do excipient choices impact the formulation’s stability and bioavailability?

Excipients influence shelf life, efficacy, patient compliance, and manufacturing efficiency. Microcrystalline cellulose enhances tablet integrity, while croscarmellose sodium ensures rapid disintegration. Magnesium stearate reduces friction during compression but can affect dissolution if used excessively. Selection of non-reactive, biocompatible excipients preserves chemical stability and aids in predictable drug release. For formulations with modified release, polymers like HPMC delay drug release, supporting sustained analgesic effects.

What are the key themes in excipient strategy for ASSURED IBUPROFEN?

1. Enhancing consumer adherence through taste-masking and ease of swallowing

Efforts focus on flavoring agents and formulation adjustments, such as orally disintegrating tablets (ODTs). Use of sweeteners (e.g., sodium saccharin) and flavoring agents (e.g., mint, cherry) improves palatability. ODTs employ disintegrants like crospovidone, which permit rapid disintegration without water, improving adherence in pediatric and elderly populations.

2. Improving stability and shelf life

Selection of excipients with proven chemical inertness diminishes the risk of degradation. Protecting ibuprofen from moisture and light involves using desiccants, tight packaging, and excipients such as colloidal silica as anti-caking agents. Freeze-dried powder formulations or coated tablets can extend shelf life.

3. Supporting manufacturing efficiency

Excipient compatibility with high-speed manufacturing processes reduces production costs. Microcrystalline cellulose provides good flow properties, enabling large batch consistency. Lubricants like magnesium stearate facilitate efficient tablet compression.

4. Ensuring regulatory compliance and excipient safety

Preference for GRAS (Generally Recognized As Safe) excipients ensures compliance across markets (FDA, EMA). Use of approved excipients in controlled quantities minimizes regulatory hurdles.

What are the commercial opportunities tied to excipient strategies?

1. Differentiation through formulation innovation

Creating pediatric-friendly, fast-dissolving, or sustained-release formulations opens new market segments. The global OTC ibuprofen market reached approximately USD 4.2 billion in 2022, with growth driven by formulations tailored for specific populations [1].

2. Extension into niche markets

Specialized formulations with excipients targeting distinct needs—such as gluten-free, vegan, or allergen-free options—can command premium pricing. There is increasing demand from consumers seeking free-from products, which influences excipient selection.

3. Licensing and collaborations

Partnering with excipient manufacturers offering novel excipients, such as bio-adhesive polymers or taste-masking agents, provides opportunities for differentiated products and patent extensions. These partnerships support innovation while reducing R&D costs.

4. Supply chain resilience

Securing multiple sources of key excipients like microcrystalline cellulose and disintegrants shields production against shortages and price fluctuations, maintaining supply continuity in competitive markets.

What regulatory considerations influence excipient strategy?

Regulatory authorities require comprehensive safety data for excipients, especially in pediatric or chronic-use formulations. Compatibility, stability, and non-interference with active drug release are critical. Recent updates favor transparency about excipient sources and potential allergen content. Regulatory pathways favor excipients with established safety profiles, reducing approval times.

How does the excipient landscape vary across markets?

The US FDA and EMA maintain strict lists of approved excipients with well-documented safety profiles. For emerging markets, excipient approvals can be less comprehensive, requiring early regulatory engagement to ensure compliance. International formulations often adopt globally recognized excipients to streamline approval processes.

What are key trends influencing excipient choices for ASSURED IBUPROFEN?

  • Shift toward natural and plant-based excipients to meet consumer preferences.
  • Development of functional excipients that provide added benefits, such as mucoadhesive properties.
  • Innovation in taste-masking technologies for better pediatric acceptability.
  • Adoption of film-coatings for taste masking, moisture protection, and controlled release.

Summary table: Excipient Strategies and Opportunities

Aspect Details Opportunities
Formulation innovation Pediatric, ODT, sustained-release New market segments, premium pricing
Excipient selection GRAS, allergen-free, natural options Consumer appeal, regulatory ease
Manufacturing efficiency Flow agents, lubricants, compatible binders Cost reduction, high-speed production
Stability enhancement Moisture barriers, desiccants Shelf-life extension
Regulatory compliance Transparency, safety data Faster approvals, market access

Key Takeaways

  • Excipient choices in ASSURED IBUPROFEN target stability, bioavailability, patient compliance, and regulatory compliance.
  • Formulation innovation includes taste-masking, disintegration, and controlled release tailored to consumer needs.
  • Commercial opportunities include premium formulations, niche markets, and licensing collaborations.
  • Regulatory and market-specific variations influence excipient selection and innovation pathways.
  • Current trends favor natural, functional, and cost-effective excipient solutions aligned with consumer preferences.

FAQs

1. How important is taste-masking in IBUPROFEN formulations?
Critical for pediatric and elderly populations, taste-masking enhances compliance. Uses sweeteners, flavoring agents, and coating technologies.

2. What excipients are preferred for sustained-release IBUPROFEN?
Hydroxypropyl methylcellulose (HPMC), ethylcellulose, and other polymeric matrices control drug release.

3. Can new excipients extend the shelf life of IBUPROFEN?
Yes. Moisture barriers, desiccants, and inert carriers prevent degradation, extending shelf life.

4. Are natural excipients viable for OTC IBUPROFEN?
Yes. Regulatory bodies accept natural excipients with documented safety. They also align with consumer trends.

5. How do regulatory differences impact excipient choice globally?
Stringent agencies like FDA and EMA favor well-documented, approved excipients; emerging markets may have more flexible requirements, influencing formulation choices.


References

[1] MarketResearch.com. (2022). Over-the-counter (OTC) analgesics market analysis.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.